Axonics, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2024-11-15: Form 8-K; Period of report 2024-11-15; Description 2.01 Completion of Acquisition or Disposition of Assets; 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; 3.03 Material Modification to Rights of Security Holders; 5.01 Changes in Control of Registrant; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; Details 2.01.
- 2024-11-07: Form 8-K; Period of report 2024-11-07; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2024-08-01: Form 8-K; Period of report 2024-08-01; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2024-04-30: Form 8-K; Period of report 2024-04-30; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2024-11-15 | 8-K | 2024-11-15 | 2.01 Completion of Acquisition or Disposition of Assets; 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; 3.03 Material Modification to Rights of Security Holders; 5.01 Changes in Control of Registrant; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 2.01 As described in the Introductory Note of this Current Report on Form 8-K, on November 15, 2024, the Merger was completed. 3.01 The disclosure under the Introductory Note to this Current Report on Form 8-K is incorporated by reference into this Item 3.01. 3.03 At the Effective Time, as a result of the consummation of the Merger, each holder of Shares outstanding immediately prior to the Effective Time (other than the Excluded Shares, which were cancelled as of the Effective Time) ceased to have any rights as a stockholder of the Company (other than (i) in the case of Shares other than the Dissenting Shares, the right to receive the Merger Consideration for such stockholder’s Shares and (ii) in the case of Dissenting Shares only, the right to receive only the payment provided by Section 262 of the DGCL in respect of such Dissenting Shares), except as otherwise described above. 5.01 The disclosures under the Introductory Note and Items 2.01, 3.01, 3.03, 5.02 and 5.03 of this Current Report on Form 8-K are incorporated by reference into this Item 5.01. 5.02 The disclosures under the Introductory Note and Item 2.01 of this Current Report on Form 8-K are incorporated by reference into this Item 5.02. 5.03 Pursuant to the Merger Agreement, effective as of the Effective Time, the Amended and Restated Certificate of Incorporation of the Company, as amended, and the Amended and Restated Bylaws of the Company, as amended, were each amended and restated in their entirety, as set forth in Exhibits 3.1 and 3.2, respectively, to this Current Report on Form 8-K, which are incorporated by reference into this Item 5.03. | axnx-20241115.htm |
| 2024-11-07 | 8-K | 2024-11-07 | 2.02 Results of Operations and Financial Condition | 2.02 On November 7, 2024, Axonics, Inc. (the Company) issued a press release announcing its financial results for the quarter ended September 30, 2024. | axnx-20241107.htm |
| 2024-08-01 | 8-K | 2024-08-01 | 2.02 Results of Operations and Financial Condition | 2.02 On August 1, 2024, Axonics, Inc. (the Company) issued a press release announcing its financial results for the quarter ended June 30, 2024. | axnx-20240801.htm |
| 2024-04-30 | 8-K | 2024-04-30 | 2.02 Results of Operations and Financial Condition | 2.02 On April 30, 2024, Axonics, Inc. (the Company) issued a press release announcing its financial results for the quarter ended March 31, 2024. | axnx-20240430.htm |
| 2024-04-04 | 8-K | 2024-04-03 | 8.01 Other Events | 8.01 As previously disclosed, on January 8, 2024, Axonics, Inc., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Boston Scientific Corporation, a Delaware corporation (“Boston Scientific”), and Sadie Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Boston Scientific (“Merger Sub”), providing for the merger of Merger Sub with and into the Company (the “Merger”), with the Company surviving the Merger as a wholly owned subsidiary of Boston Scientific. | axnx-20240403.htm |
| 2024-03-25 | 8-K | 2024-03-22 | 5.07 Submission of Matters to a Vote of Security Holders; 8.01 Other Events | 5.07 Axonics, Inc. (the “Company”) held a special meeting of its stockholders (the “Special Meeting”) on March 22, 2024, to vote on the three proposals described in the Company’s definitive proxy statement filed with the U.S. Securities and Exchange Commission on February 22, 2024, and mailed to the Company’s stockholders on or about February 22, 2024 (the “Proxy Statement”). 8.01 On March 22, 2024, the Company issued a press release announcing the adoption of the Merger Agreement by the Company’s stockholders at the Special Meeting. | axnx-20240322.htm |
| 2024-02-28 | 8-K | 2024-02-28 | 2.02 Results of Operations and Financial Condition | 2.02 On February 28, 2024, Axonics, Inc. (the Company) issued a press release announcing its financial results for the quarter and fiscal year ended December 31, 2023. | axnx-20240228.htm |
| 2024-01-08 | 8-K | 2024-01-08 | 1.01 Entry into a Material Definitive Agreement; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 1.01 Entry into a Material Definitive Agreement. | axnx-20240108.htm |
| 2024-01-08 | 8-K | 2024-01-08 | 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure | 2.02 On January 8, 2024, Axonics, Inc., a Delaware corporation (the “Company” or “Axonics”), issued a press release announcing its preliminary unaudited revenue for the fourth quarter and fiscal year ended December 31, 2023, based on the information and data currently available. 7.01 On January 8, 2024, the Company issued a press release announcing that the Company and Boston Scientific Corporation, a Delaware corporation (“Boston Scientific”), have executed a definitive agreement pursuant to which the Company will be acquired by Boston Scientific on the terms and subject to the conditions set forth in the definitive agreement. | axnx-20240108.htm |
| 2023-10-30 | 8-K | 2023-10-30 | 2.02 Results of Operations and Financial Condition | 2.02 On October 30, 2023, Axonics, Inc. (the Company) issued a press release announcing its financial results for the quarter ended September 30, 2023. | axnx-20231030.htm |
| 2023-10-04 | 8-K | 2023-10-02 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 As previously reported by Axonics, Inc. (the “Company”) in the current report on Form 8-K filed on August 21, 2023, Dan L. Dearen, President and Chief Financial Officer (Principal Financial and Accounting Officer) of the Company, will retire from the Company effective October 2, 2023 and the Company has appointed Kari Keese to serve as Chief Financial Officer (Principal Financial and Accounting Officer) of the Company effective upon Mr. Dearen’s exit. | axnx-20231002.htm |
| 2023-08-21 | 8-K | 2023-08-18 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure | 5.02 On August 18, 2023, Dan L. Dearen, President and Chief Financial Officer (Principal Financial and Accounting Officer) of Axonics, Inc. (the “Company”), provided formal notice of his decision to retire from the Company effective October 2, 2023. 7.01 On August 21, 2023, the Company issued a press release announcing the events described in Item 5.02 of this Current Report on Form 8-K and reaffirming its fiscal year 2023 revenue guidance. | axnx-20230818.htm |
| 2023-07-27 | 8-K | 2023-07-27 | 2.02 Results of Operations and Financial Condition | 2.02 On July 27, 2023, Axonics, Inc. (the Company) issued a press release announcing its financial results for the quarter ended June 30, 2023. | axnx-20230727.htm |
| 2023-06-27 | 8-K | 2023-06-26 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 Axonics, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”) on June 26, 2023. | axnx-20230626.htm |
| 2023-05-18 | 8-K | 2023-05-18 | 8.01 Other Events | 8.01 On May 18, 2023, Axonics, Inc. (the “Company”) filed with the Securities and Exchange Commission, a prospectus supplement dated May 18, 2023 to the Company’s automatic shelf registration statement on Form S-3 (Registration No. 333-271663). | axnx-20230518.htm |
| 2023-05-01 | 8-K | 2023-05-01 | 2.02 Results of Operations and Financial Condition | 2.02 On May 1, 2023, Axonics, Inc. (the Company) issued a press release announcing its financial results for the quarter ended March 31, 2023. | axnx-20230501.htm |
| 2023-04-06 | 8-K | 2023-04-01 | 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | 1.01 Entry into a Material Definitive Agreement. 1.02 In conjunction with the Company’s entry into the Lease and the Third Amendment, on April 1, 2023, the Company terminated its lease with Irvine Business Center LLC for its existing premises at 7575 Irvine Center Drive (the “Irvine Center Premises”), and its lease with Irvine Company for its existing premises at 26 Technology Drive (the “Technology Premises”) and 15326 Alton Parkway (the “Alton Premises”). 2.03 The description of the Lease in Item 1.01 is incorporated by reference into this Item 2.03. | axnx-20230401.htm |
| 2023-03-01 | 8-K | 2023-03-01 | 2.02 Results of Operations and Financial Condition | 2.02 On March 1, 2023, Axonics, Inc. (the Company) issued a press release announcing its financial results for the quarter and fiscal year ended December 31, 2022. | axnx-20230301.htm |
| 2023-01-11 | 8-K | 2023-01-11 | 2.02 Results of Operations and Financial Condition | 2.02 On January 11, 2023, Axonics, Inc. (the Company) issued a press release announcing its preliminary unaudited revenue for the fiscal year ended December 31, 2022, based on the information and data currently available. | axnx-20230111.htm |
| 2022-10-31 | 8-K | 2022-10-31 | 2.02 Results of Operations and Financial Condition | 2.02 On October 31, 2022, Axonics, Inc. (the Company) issued a press release announcing its financial results for the quarter ended September 30, 2022. | axnx-20221031.htm |
| 2022-08-05 | 8-K | 2022-08-02 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 8.01 On August 2, 2022, the Company issued press releases announcing that it had launched and priced the Offering, and on August 5, 2022, the Company issued a press release announcing the closing of the Offering. | axnx-20220802.htm |
| 2022-08-01 | 8-K | 2022-08-01 | 2.02 Results of Operations and Financial Condition | 2.02 On August 1, 2022, Axonics, Inc. (the Company) issued a press release announcing its financial results for the quarter ended June 30, 2022. | axnx-20220801.htm |
| 2022-06-01 | 8-K | 2022-05-25 | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 5.07 Submission of Matters to a Vote of Security Holders | 5.03 On May 31, 2022, Axonics, Inc. (the “Company”) amended its Amended and Restated Certificate of Incorporation (as amended, the “Charter”) to: (i) increase the number of authorized shares of the Company’s capital stock from 60,000,000 shares to 85,000,000 shares, and the number of authorized shares of the Company’s common stock from 50,000,000 shares to 75,000,000 shares; (ii) reduce the vote required for the Company’s stockholders to amend, alter or repeal the Company’s Amended and Restated Bylaws (the “Bylaws”) from (A) 66 2/3% in voting power of the outstanding shares of the Company’s capital stock entitled to vote thereon, to (B) a majority in voting power of the outstanding shares of the Company’s capital stock entitled to vote thereon; and (iii) reduce the vote required to amend, repeal, or adopt any provisions of the Charter from (A) the affirmative vote of the holders of at least 66 2/3% of the voting power of the shares of the Company’s outstanding stock entitled to vote thereon, voting together as a single class, to (B) the affirmative vote of a majority of the voting power of the shares of the Company’s outstanding stock entitled to vote thereon, voting together as a single class (collectively, the “Charter Amendment”). 5.07 The Company held the Annual Meeting on May 25, 2022. | axnx-20220525.htm |
| 2022-05-05 | 8-K | 2022-05-05 | 2.02 Results of Operations and Financial Condition | 2.02 On May 5, 2022, Axonics, Inc. (the Company) issued a press release announcing its financial results for the quarter ended March 31, 2022. | axnx-20220505.htm |
| 2022-03-08 | 8-K | 2022-03-07 | 8.01 Other Events | 8.01 On March 7, 2022, Axonics, Inc. (the Company) issued a press release announcing its receipt of approval from the U.S. Food and Drug Administration for its recharge-free sacral neuromodulation system. | axnx-20220307.htm |
| 2022-02-24 | 8-K | 2022-02-24 | 2.02 Results of Operations and Financial Condition | 2.02 On February 24, 2022, Axonics, Inc. (the Company) issued a press release announcing its financial results for the quarter and fiscal year ended December 31, 2021. | axnx-20220224.htm |
| 2022-01-06 | 8-K | 2022-01-06 | 2.02 Results of Operations and Financial Condition | 2.02 On January 6, 2022, Axonics, Inc. (the Company) issued a press release announcing its preliminary unaudited revenue for the fourth quarter ended December 31, 2021, based on the information and data currently available. | axnx-20220106.htm |
| 2021-11-04 | 8-K | 2021-11-04 | 2.02 Results of Operations and Financial Condition | 2.02 On November 4, 2021, Axonics, Inc. (the Company) issued a press release announcing its financial results for the quarter ended September 30, 2021. | axnx-20211104.htm |
| 2021-08-05 | 8-K | 2021-08-05 | 2.02 Results of Operations and Financial Condition | 2.02 On August 5, 2021, Axonics, Inc. (the Company) issued a press release announcing its financial results for the quarter ended June 30, 2021. | axnx-20210805.htm |
| 2021-07-19 | 8-K | 2021-07-15 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 5.02 The Board of Directors (the “Board”) of Axonics, Inc. (the “Company”) has appointed Dr. Esteban López M.D., to serve as a member of the Board, effective July 15, 2021. 8.01 On July 15, 2021, the Company issued a press release announcing certain of the matters described in Item 5.02 of this Current Report on Form 8-K. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. | axnx-20210715.htm |
| 2021-06-25 | 8-K | 2021-06-23 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 Axonics, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”) on June 23, 2021. | axnx-20210623.htm |
| 2021-06-21 | 8-K | 2021-06-16 | 8.01 Other Events | 8.01 On June 16, 2021, Axonics, Inc. (the “Company”) prepaid the principal amount of $75 million plus all other outstanding amounts in full under its Loan and Security Agreement (the “Agreement”) with the lenders from time to time party thereto and Silicon Valley Bank, as the administrative agent and collateral agent for the lenders. | axnx-20210616.htm |
| 2021-05-14 | 8-K | 2021-05-11 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 8.01 On May 11, 2021, the Company issued press releases announcing that it had launched and priced the Offering, and on May 14, 2021, the Company issued a press release announcing the closing of the Offering. | axnx-20210511.htm |
| 2021-05-06 | 8-K | 2021-05-06 | 2.02 Results of Operations and Financial Condition | 2.02 On May 6, 2021, Axonics, Inc. (the Company) issued a press release announcing its financial results for the quarter ended March 31, 2021. | axnx-20210506.htm |
| 2021-05-05 | 8-K | 2021-04-30 | 8.01 Other Events | 8.01 On April 30, 2021, Axonics, Inc. (the “Company”) filed with the Securities and Exchange Commission, a prospectus supplement dated April 30, 2021 to the Company’s automatic shelf registration statement on Form S-3 (Registration No. 333-238064). | axnx-20210430.htm |
| 2021-04-01 | 8-K | 2021-03-31 | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 5.03 On March 31, 2021, Axonics, Inc. (formerly Axonics Modulation Technologies, Inc.), a Delaware corporation (the “Company”) filed with the Secretary of State of the State of Delaware a Certificate of Amendment (the “Certificate of Amendment”) to its Amended and Restated Certificate of Incorporation, to change its corporate name from “Axonics Modulation Technologies, Inc.” to “Axonics, Inc.” effective as of March 31, 2021. | axnx-20210331.htm |
| 2021-03-03 | 8-K | 2021-02-25 | 1.01 Entry into a Material Definitive Agreement; 2.01 Completion of Acquisition or Disposition of Assets; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities; 7.01 Regulation FD Disclosure; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 2.01 The information set forth under Item 1.01, “Agreement Relating to the Sale and Purchase of the Share Capital of Contura Limited” is incorporated herein by reference. 2.03 The information set forth under Item 1.01, “Loan and Security Agreement” is incorporated herein by reference. 3.02 The disclosure set forth above in Item 1.01 with respect to the Stock Consideration pursuant to the Purchase Agreement is incorporated by reference herein. 7.01 On February 25, 2021, the Company issued a press release announcing its entry into the Purchase Agreement and the transactions contemplated thereby. 8.01 On March 2, 2021, the Company issued 65,594 shares of its common stock, $0.0001 par value, to Micro Systems Engineering, Inc. (“MST”), pursuant to an effective shelf registration statement on Form S-3 (Registration No. 333-238064) and a related prospectus supplement filed with the Securities and Exchange Commission on March 2, 2021. | axnx-20210225.htm |
| 2021-02-25 | 8-K | 2021-02-25 | 2.02 Results of Operations and Financial Condition | 2.02 On February 25, 2021, Axonics Modulation Technologies, Inc. (the Company) issued a press release announcing its financial results for the quarter ended December 31, 2020. | axnx-20210225.htm |
| 2021-01-25 | 8-K | 2021-01-25 | 2.02 Results of Operations and Financial Condition | 2.02 On January 25, 2021, Axonics Modulation Technologies, Inc. (the Company) issued a press release announcing its preliminary unaudited revenue for the fourth quarter ended December 31, 2020, based on the information and data currently available. | axnx-20210125.htm |
| 2020-12-14 | 8-K | 2020-12-11 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 5.02 The Board of Directors (the Board) of Axonics Modulation Technologies, Inc. (the Company) has appointed David M. Demski, to serve as a member of the Board and the Audit Committee of the Board, effective January 1, 2021. 8.01 On December 14, 2020, the Company issued a press release announcing certain of the matters described in Item 5.02 of this Current Report on Form 8-K. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. | axnx-20201211.htm |
| 2020-11-04 | 8-K | 2020-11-04 | 2.02 Results of Operations and Financial Condition | 2.02 On November 4, 2020, Axonics Modulation Technologies, Inc. (the Company) issued a press release announcing its financial results for the quarter ended September 30, 2020. | axnx-20201104.htm |
| 2020-08-06 | 8-K | 2020-08-06 | 2.02 Results of Operations and Financial Condition | 2.02 On August 6, 2020, Axonics Modulation Technologies, Inc. (the Company) issued a press release announcing its financial results for the quarter ended June 30, 2020. | axnx-063020x8kdocument.htm |
| 2020-07-13 | 8-K | 2020-07-13 | 2.02 Results of Operations and Financial Condition | 2.02 On July 13, 2020, Axonics Modulation Technologies, Inc. (the “Company”) issued a press release announcing its preliminary unaudited revenue for the second quarter ended June 30, 2020 and unaudited cash, cash equivalents and short term investments as of June 30, 2020, based on the information and data currently available. | axnx-071320x8kdocument.htm |
| 2020-06-26 | 8-K | 2020-06-24 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 Axonics Modulation Technologies, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”) on June 24, 2020. | axnx-062420x8kdocument.htm |
| 2020-05-12 | 8-K | 2020-05-07 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 On May 7, 2020, Axonics Modulation Technologies, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with BofA Securities, Inc., Morgan Stanley & Co. LLC and Wells Fargo Securities, LLC, as representatives of the several underwriters named therein (the “Underwriters”), relating to an underwritten public offering (the “Offering”) of 4,000,000 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”). 8.01 On May 7, 2020, the Company issued press releases announcing that it had launched and priced the Offering, and on May 12, 2020, the Company issued a press release announcing the closing of the Offering. | axnx-050720x8kdocument.htm |
| 2020-05-05 | 8-K | 2020-05-05 | 2.02 Results of Operations and Financial Condition | 2.02 On May 5, 2020, Axonics Modulation Technologies, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2020. | axnx-033120x8kdocument.htm |
| 2020-05-04 | 8-K | 2020-04-28 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 5.02 On April 28, 2020, Raphaël Wisniewski resigned from the Board of Directors (the “Board”) of Axonics Modulation Technologies, Inc. (the “Company”), and in doing so left positions as the Chairman of the Board and Chair of the Compensation Committee of the Board. 8.01 On April 29, 2020, the Company issued a press release announcing certain of the matters described in Item 5.02 of this Current Report on Form 8-K. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. | axnx-042820x8kdocument.htm |
| 2020-04-16 | 8-K | 2020-04-16 | 8.01 Other Events | 8.01 Axonics Modulation Technologies, Inc. (the “Company”) determined that in light of the uncertainty created by the COVID 19 pandemic and its anticipated impact on the Company’s operations, most employees will be taking a temporary 20% reduction in base salary for the remainder of the second quarter of 2020. | axnx-041620x8kdocument.htm |
| 2020-03-04 | 8-K | 2020-03-04 | 2.02 Results of Operations and Financial Condition | 2.02 On March 4, 2020, Axonics Modulation Technologies, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended December 31, 2019. | axnx-123119x8kdocument.htm |
| 2020-01-09 | 8-K | 2020-01-09 | 2.02 Results of Operations and Financial Condition | 2.02 On January 9, 2020, Axonics Modulation Technologies, Inc. (the “Company”) issued a press release announcing its preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2019 and unaudited cash, cash equivalents and short term investments as of December 31, 2019, based on the information and data currently available. | axnx-01092020x8kdocument.htm |
| 2020-01-02 | 8-K | 2019-12-30 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | axnx-123019x8kdocument.htm |
| 2019-12-12 | 8-K | 2019-12-12 | 8.01 Other Events | 8.01 On December 12, 2019, Axonics Modulation Technologies, Inc. (the “Company”) issued a press release announcing that the underwriters of its follow-on public offering exercised in full their option to purchase an additional 750,000 shares of common stock from the Company at the offering price of $22.00 per share, less underwriting discounts and commissions. | axnx-121219x8kdocument.htm |
| 2019-11-22 | 8-K | 2019-11-22 | 8.01 Other Events | 8.01 On November 22, 2019, Axonics Modulation Technologies, Inc. (the “Company”) issued a press release announcing the closing of its previously announced underwritten public offering of 5,000,000 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), of which 4,595,000 shares of Common Stock were sold by the Company and 405,000 shares of Common Stock were sold by certain stockholders of the Company. | axnx-112219x8kdocument.htm |
| 2019-11-20 | 8-K | 2019-11-19 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 8.01 On November 19, 2019, the Company issued a press release announcing that it had launched the Offering, and on November 19, 2019, the Company issued a press release announcing that it had priced the Offering. | axnx-111919x8kdocument.htm |
| 2019-11-14 | 8-K | 2019-11-14 | 8.01 Other Events | 8.01 On November 14, 2019, Axonics Modulation Technologies, Inc. (the “Company”) issued a press release announcing its receipt of approval from the U.S. Food and Drug Administration for its r-SNM System for the clinical indications of overactive bladder and urinary retention. | axnx-111419x8kdocument.htm |
| 2019-11-14 | 8-K | 2019-11-14 | 2.02 Results of Operations and Financial Condition | 2.02 On November 14, 2019, Axonics Modulation Technologies, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2019. | axnx-093019x8kdocument.htm |
| 2019-11-06 | 8-K | 2019-11-05 | 8.01 Other Events | 8.01 On November 5, 2019, Axonics Modulation Technologies, Inc. (the “Company”) issued a press release announcing that it received notice that Medtronic, Inc., Medtronic Puerto Rico Operations Co., Medtronic Logistics LLC and its U.S. operating company Medtronic USA, Inc. (collectively, “Medtronic”) filed a lawsuit against the Company in the United States District Court for the Central District of California. | axnx-110519x8kdocument.htm |
| 2019-09-09 | 8-K | 2019-09-09 | 8.01 Other Events | 8.01 On September 9, 2019, Axonics Modulation Technologies, Inc. (the “Company”) issued a press release announcing its receipt of approval from the U.S. Food and Drug Administration for its r-SNM System for the clinical indication of fecal incontinence. | axnx-090919x8kdocument.htm |
| 2019-08-22 | 8-K | 2019-08-19 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 Axonics Modulation Technologies, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”) on August 19, 2019. | axnx-082219x8kdocument.htm |
| 2019-08-05 | 8-K | 2019-08-05 | 2.02 Results of Operations and Financial Condition | 2.02 On August 5, 2019, Axonics Modulation Technologies, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2019. | axnx-063019x8kdocument.htm |
| 2019-07-12 | 8-K | 2019-06-28 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | axnx-062819x8kdocument.htm |
| 2019-06-11 | 8-K | 2019-06-05 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On June 5, 2019, Axonics Modulation Technologies, Inc. (the “Company”) entered into Executive Employment Agreements with each of its named executive officers, Raymond W. Cohen, Dan L. Dearen and Rinda K. Sama, to replace the existing employment agreements which expire by their terms on July 1, 2019, or in the case of Mr. Sama, May 20, 2019. | axnx-060519x8kdocument.htm |
| 2019-05-08 | 8-K | 2019-05-08 | 2.02 Results of Operations and Financial Condition | 2.02 On May 8, 2019, Axonics Modulation Technologies, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2019. | axnx-033119x8kdocument.htm |
| 2019-04-12 | 8-K | 2019-04-08 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 5.02 The Board of Directors (the “Board”) of Axonics Modulation Technologies, Inc. (the “Company”) has appointed Nancy Snyderman, M.D., FACS, to serve as a member of the Board and the Nominating and Corporate Governance Committee of the Board, effective as of April 8, 2019. 8.01 On April 8, 2019, the Company issued a press release announcing certain of the matters described in Item 5.02 of this Current Report on Form 8-K. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. | d723435d8k.htm |
| 2019-03-05 | 8-K | 2019-03-05 | 2.02 Results of Operations and Financial Condition | 2.02 On March 5, 2019, Axonics Modulation Technologies, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended December 31, 2018. | axnx-123118x8kdocument.htm |
| 2019-03-05 | 8-K | 2019-02-27 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 5.02 The Board of Directors (the “Board”) of Axonics Modulation Technologies, Inc. (the “Company”) has appointed Michael H. Carrel to serve as a member of the Board and the Audit Committee of the Board, effective as of February 27, 2019. 8.01 On March 4, 2019, the Company issued a press release announcing certain of the matters described in Item 5.02 of this Current Report on Form 8-K. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. | axnx-022719x8kdocument.htm |
| 2018-12-11 | 8-K | 2018-12-11 | 2.02 Results of Operations and Financial Condition | 2.02 On December 11, 2018, Axonics Modulation Technologies, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2018. | a2018q38-kdocument.htm |
| 2018-11-05 | 8-K | 2018-11-01 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 8.01 Other Events | 5.02 Effective upon the closing of the initial public offering of common stock of Axonics Modulation Technologies, Inc. (the “Company”) on November 2, 2018 (the “Initial Public Offering”), as described below, and pursuant to resolutions previously adopted by the Company’s Board of Directors, Robert E. McNamara became a member of the Company’s Board of Directors and the Chairman of the Audit Committee of the Company’s Board of Directors. 5.03 On November 1, 2018, the Company filed an Amended and Restated Certificate of Incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware in connection with the closing of the Initial Public Offering. 8.01 On November 2, 2018, the Company completed its Initial Public Offering of 8,000,000 shares of its common stock at an initial public offering price of $15.00 per share, before underwriting discounts and commissions. | d485184d8k.htm |